F-Prime Capital

F-Prime Capital is a venture capital firm established in 1969 and headquartered in Cambridge, Massachusetts, with additional offices in San Francisco and London. It is part of the Fidelity Investments family, which has a long history of supporting entrepreneurs. F-Prime Capital focuses its investments on companies in North America and Europe, specializing in sectors such as healthcare, life sciences, therapeutics, fashion, medtech, health information technology and services, and technology. The firm emphasizes a hands-on approach, leveraging its deep industry expertise and extensive relationships to assist entrepreneurs in building significant companies. F-Prime Capital operates without the pressures of external fundraising, allowing it to concentrate on identifying and nurturing promising ventures.

Abdul Abdirahman

Principal

Sanjay Aggarwal

Venture Partner

Jessica Alston

Partner

Nikhil Ananth

Senior Associate

Hannah Arnold

Principal

Raj Basak

Associate

Kevin Chu

Principal

Lucille Conroy

Senior Associate

Brett Cook

Partner

Shervin Ghaemmagham

Operating Partner

Shervin Ghaemmaghami

Investor

Benjamin Gorman

Venture Partner

Ben Gorman

Principal

David Jegen

Managing Partner

Sarah Lamont

Senior Associate

Erica Lee

Senior Associate

Connie Li

Associate

Jon Lim

Partner

Muzammil Mansuri

Venture Partner

Julia McDowell

Venture Partner

Betsy Mule

Senior Associate

Alex Pasteur

Partner

Ketan Patel

Partner

Sachin Patodia

Partner

Cameron Raglin

Associate

Brett J. Rome

Venture Partner

Mihir Shah

Venture Partner

Siyu Shi Ph.D

Associate

Nihal Sinha

Principal

Anastasiya Sybirna

Senior Associate

Martin Taylor Ph.D

Principal

Gaurav Tuli

Partner

Jennifer Uhrig

Senior Managing Director

Bala Varadhan

Principal

Robert Weisskoff

Partner

Stacie Weninger Ph.D

President, FBRI

Alex Wong

Associate

Rocio Wu

Principal

Chong Xu

Partner

Brian Yordy

Principal

Michael Zheng

Venture Partner

Jessica Alston

Principal

Julia McDowell

Venture Partner

Past deals in Series B

Notabene

Series B in 2024
Notabene, Inc. is a New York-based company that offers a software as a service (SaaS) platform focused on crypto compliance for the financial industry. Established in 2020, Notabene provides businesses with tools to meet emerging global regulations for cryptocurrency transactions, particularly the Travel Rule. Its platform features a unified API and a comprehensive dashboard designed to assist compliance officers in managing risks associated with both Travel Rule and non-custodial transactions. By simplifying compliance processes, Notabene enables financial companies to engage with a broader range of crypto businesses, enhancing transaction confidence and supporting growth in their operations.

Expressable

Series B in 2024
Expressable is an online speech therapy practice that focuses on enhancing communication for individuals with speech and language disorders, particularly children. By employing a parent-focused care model, Expressable integrates speech therapy techniques into the daily lives of users, thereby improving outcomes and experiences. The platform offers a range of services, including therapy for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. It facilitates consistent practice through weekly activities, enabling users to develop their communication skills effectively.

Quantum Circuits

Venture Round in 2024
Quantum Circuits, Inc. specializes in the development and manufacture of quantum computers utilizing superconducting devices. Founded in 2015 and located in New Haven, Connecticut, the company aims to innovate in the field of quantum computing by delivering full-stack systems that efficiently scale. Led by Dr. Robert Schoelkopf, a prominent figure in quantum science, Quantum Circuits employs a unique dual-rail quantum qubit design that incorporates built-in hardware error detection and conversion. This approach allows for a highly scalable error-corrected system, requiring significantly fewer physical qubits per logical qubit and providing a more efficient pathway to fault-tolerant quantum computing. By focusing on solid-state quantum bits, the company enables clients to perform error-free computations, thereby accelerating research and advancing the practical applications of quantum technology.

Engrail Therapeutics

Series B in 2024
Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

HiLabs

Series B in 2024
HiLabs is a developer of a healthcare data mining platform that aims to enhance data-driven decision-making within healthcare organizations. Recognizing that these organizations possess invaluable domain knowledge, HiLabs provides tools that enable them to harness this expertise alongside their data. The platform employs artificial intelligence to allow healthcare professionals to intuitively explore their data, interact with visualizations, customize dashboards, and generate new attributes. This empowers users to independently uncover novel insights and better understand client health data, ultimately facilitating more effective healthcare management and decision-making.

Nocion Therapeutics

Series B in 2024
Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment of serious conditions including cough, itch, pain and inflammation.

Comanche Biopharma

Series B in 2024
Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Eleos Health

Series B in 2023
Eleos Health develops innovative health technology solutions aimed at enhancing decision-making for clinicians in the behavioral health sector. The company's AI-powered Speech-to-Insights system operates during mental health sessions to analyze voice data in real time. By gathering insights on patients through this voice technology, Eleos Health enables clinicians to deliver personalized, efficient, and cost-effective care. The automated nature of the system helps streamline the clinical process, ultimately supporting mental health professionals in providing the necessary care and support for their patients.

Doceree

Series B in 2023
Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree specializes in connecting pharmaceutical and healthcare brands with healthcare professionals (HCPs). The platform enables targeted advertising and provides data analytics to help clients effectively reach and engage with HCPs in a compliant manner. Utilizing artificial intelligence and data segmentation, Doceree identifies specific HCPs across various digital platforms, including physician networking sites, medical journals, and telemedicine platforms. This approach allows healthcare industry professionals to deliver precise and transparent messaging at scale, catering to the needs of media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals.

Better Life Partners

Series B in 2023
Better Life Partners Inc. is a healthcare provider based in Hanover, New Hampshire, focused on supporting individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners utilizes technology to create personalized care plans that adapt to clients' needs, ensuring effective healthcare delivery through telehealth and community-based solutions. By integrating medical and behavioral healthcare, the company aims to address the complex needs of patients, providing comprehensive support to help them recover from addiction. Better Life Partners has additional offices across various locations in New Hampshire, reflecting its commitment to serving vulnerable populations.

K36 Therapeutics

Series B in 2023
K36 Therapeutics is engaged in the development of small molecule therapeutics aimed at treating cancer. The company focuses on translating epigenetic modulation of oncogenic pathways into effective therapies, utilizing technology to create orally bioavailable small molecules and selective inhibitors. This innovative approach enables healthcare professionals to enhance treatment options for cancer patients, addressing the complexities of oncogenic pathways and improving therapeutic outcomes.

Tradier

Series B in 2023
Tradier Inc. is a financial services company based in Charlotte, North Carolina, founded in 2014. It operates a cloud-based trading and investing platform designed to enhance trade execution for investors, advisers, and traders. The platform provides access to real-time market data and facilitates seamless account opening and funding. Tradier's innovative solution includes a set of fully hosted APIs, modules, and tools that cater to platform providers and developers, enabling them to create customized financial services. The company is committed to offering transparent pricing and low fees, making it easier for users to engage in trading and investment activities.

Cadence Neuroscience

Venture Round in 2023
Cadence Neuroscience, Inc. is an early-stage company focused on developing innovative medical device therapies for epilepsy, central pain, and other neurological disorders. Founded in 2017 and based in Redmond, Washington, the company is leveraging core technology developed at the Mayo Clinic, which is currently under clinical evaluation. Cadence's implantable devices are designed to detect specific brain signals and deliver tailored electrical stimulation to modify neural circuit activity. This approach aims to enhance seizure control and improve treatment methods, offering medical practitioners a customizable solution for managing neurological conditions.

Canoe

Series B in 2023
Canoe focuses on automating document management and data extraction for allocators and investors into alternatives. The company is transforming the post-investment operational, monitoring, and reporting experience for all involved. By combining industry expertise with sophisticated machine-learning and data capture technologies, it turns PDF reporting documents into actionable data and intelligence, unlocking new operational efficiencies for clients. Canoe was founded in 2013 and based in New York, New York.

NOCD

Series B in 2023
NOCD is an online OCD therapy platform that helps people with OCD get better and then stay better. With NOCD, users can have face-to-face video therapy sessions with licensed therapists that specialize in OCD, as well as get 24/7 support between sessions from self-help tools and peer communities.

Ensoma

Series B in 2023
Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach using Engenious vectors. These vectors are engineered to facilitate the delivery of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the need for stem cell collection or harmful pre-treatment procedures like chemotherapy. This unique capability allows Ensoma to administer therapies through a single injection, making it possible to deliver effective treatments in outpatient settings and areas with limited access to advanced healthcare systems. By streamlining the process of gene therapy, Ensoma aims to enhance the accessibility and curative potential of genomic medicine for patients with various diseases.

Neumora Therapeutics

Series B in 2022
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Hone

Venture Round in 2022
Hone is a live learning platform for management training that cultivates soft skills with hard data. Hone blends the best of expert-led small group training, peer learning, continuous reinforcement, and a technology platform to develop better leaders, managers, and teammates for today’s workplace. The company's platform helps to expand, connect, and let leaders analyze the impact of the training on the organization to provide improvement for team development. Hone was established in 2018 by Tom Griffiths and Savina Perez in Encinitas, California.

Vendr

Series B in 2022
Vendr, Inc. is a Boston-based company that specializes in a software-as-a-service (SaaS) platform designed to streamline the purchasing and renewal of software for businesses. Founded in 2018, Vendr offers a comprehensive suite of services, including commercial negotiations, renewal management, and contract logistics. By leveraging a vast dataset from numerous transactions, Vendr empowers finance and procurement teams to make informed decisions, find suitable software solutions, and negotiate fair prices. The platform facilitates the entire purchasing process, from discovering new tools to managing upcoming renewals, thereby helping clients to minimize software expenses. Recently, Vendr raised significant funding and expanded its capabilities through the acquisition of Blissfully, a SaaS management platform.

Invetx

Series B in 2022
Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.

Ashby

Series B in 2022
Ashby is a developer of recruitment software specifically designed for high-growth companies. The company offers an enterprise-grade platform that streamlines the hiring process, making it more effective for company leaders, recruiters, and hiring managers. By providing a user-friendly solution, Ashby enables organizations of various sizes to enhance their recruitment strategies and meet their growth objectives more efficiently.

Equip Health

Series B in 2022
Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Logixboard

Series B in 2022
Logixboard, Inc. is a Seattle-based company established in 2016 that specializes in developing a cloud platform specifically for freight forwarders. This platform enhances transparency and communication between logistics service providers and their customers. As a white-labeled customer experience software, Logixboard allows these providers to increase sales and improve customer retention by integrating seamlessly with their existing internal systems. The implementation of Logixboard's solution can be completed in less than three weeks with minimal effort from the logistics teams. Additionally, the platform offers real-time tracking and big data analytics, equipping the supply chain and logistics sector with the necessary tools to stay competitive amidst the ongoing digitization of the industry.

Papaya

Series B in 2021
Papaya is a mobile application designed to simplify the bill payment process for users by allowing them to pay any bill quickly and efficiently through their smartphones. By enabling users to take a picture of their bills and complete transactions in seconds, Papaya alleviates the stress associated with traditional payment methods such as mailing checks or navigating complex online portals. The platform serves various billers across multiple industries, facilitating faster and more reliable payments. Papaya has garnered positive feedback, achieving high ratings on app stores, and has attracted investment from notable firms. In addition to bill payments, Papaya also offers electronic money services, including online banking and international payment solutions, further enhancing its utility in the fintech space.

Lighthouse

Series B in 2021
Lighthouse is a commercial platform focused on the travel and hospitality industry, previously known as OTA Insight. The company offers a hotel management platform that visualizes and leverages data to enhance business success. Its cloud-based data intelligence tools provide real-time, actionable insights that empower hoteliers and hotel management companies to make informed revenue and distribution decisions. By facilitating customer support services, Lighthouse helps maximize property occupancy rates and drive revenue growth, transforming complex market conditions into clear, actionable strategies for its clients.

AppliedVR

Series B in 2021
AppliedVR, Inc. is a Los Angeles-based company founded in 2013 that specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, particularly for pain and anxiety management. The company’s flagship product, EaseVRx, is a VR-based prescription therapeutic that has received Breakthrough Device Designation from the FDA. By integrating principles of cognitive behavioral therapy and mindfulness, EaseVRx provides a comprehensive approach to managing chronic pain, addressing biological, psychological, and social factors. This platform allows patients to self-administer treatment at home, offering flexibility and promoting better quality of life. AppliedVR has established strategic partnerships with prominent healthcare institutions, including Cedars-Sinai and Children's Hospital Los Angeles, furthering its mission to empower patients in their pain management journey.

Notable

Series B in 2021
Notable is an AI-driven platform designed to enhance healthcare operations and improve physician-patient interactions. Deployed at over 10,000 care sites, it automates more than a million repetitive workflows daily, including processes related to registration, scheduling, authorizations, and chart reviews. The platform features a voice-powered application that organizes physician-patient conversations and dictations while securely recommending appropriate billing codes. By streamlining these tasks, Notable reduces manual workload for caregivers and fosters personalized care for patients, ultimately contributing to better financial health for healthcare providers.

Centivo

Venture Round in 2021
Centivo is a new type of health plan administrator that allows self-funded employers and clinicians to join forces and deliver high quality, affordable healthcare to their employees. An alternative to traditional insurance carriers or third-party administrators, Centivo offers the technology, network, claims processing, customer support, and population health management to fully administer health benefits for all or a portion of an employee population. The Centivo model emphasizes the partnership between individuals and their primary care team as the proper model to coordinate healthcare needs. Centivo’s clinical partners are dedicated to controlling costs and helping members navigate the healthcare system, aided by personalized patient/doctor matching tools. Members are rewarded for working with their primary care team and choosing high-value care and are supported through a user-friendly app and their concierge. Employers get an ally that diligently roots out waste and is accountable for performance. It was formed in 2017 and headquartered in New York, United States.

NOCD

Series B in 2021
NOCD is an online OCD therapy platform that helps people with OCD get better and then stay better. With NOCD, users can have face-to-face video therapy sessions with licensed therapists that specialize in OCD, as well as get 24/7 support between sessions from self-help tools and peer communities.

GYENNO Technologies

Series B in 2021
GYENNO Technologies is a digital health company developing medical devices for people with disabilities. GYENNO's products include GYENNO spoon, which helps people with hand tremors eat without stress, and the GYENNO matrix, a wearable motion and gait quantitative evaluation system for Parkinson's disease.

Embark

Series B in 2021
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

Castor

Series B in 2021
Castor is an international health-tech company founded by CEO Derk Arts, MD, Ph.D. Their cloud-based clinical data platform simplifies the entire clinical trial process, from recruitment to analysis, for researchers worldwide. More than 50,000 researchers across 90 countries are using Castor to supercharge their research. Castor’s platform has supported more than 4,000 commercial and academic studies that cover a broad range of therapeutic areas including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Researchers on the platform generate vast amounts of data from traditional and remote trials, and Castor recently reached milestones of 180,000,000 data points and 2,000,000 enrolled patients. Castor’s goal is to make the world’s research data reusable, enabling AI-driven clinical trials, and ultimately creating a future in which they maximize the impact of data through reuse.

Prime Medicine

Series B in 2021
Prime Medicine is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aiming to restore normal genetic function and address the underlying causes of various diseases. By targeting a broad spectrum of conditions with significant unmet medical needs, Prime Medicine seeks to revolutionize the field of genetic medicine through effective and efficient therapeutic solutions.

Proximie

Series B in 2021
Proximie Inc. is a health technology company based in Bedford, Massachusetts, that specializes in a telehealth platform designed for virtual surgical assistance. Founded in 2016 by Nadine Hachach-Haram, Proximie's platform enables surgeons to remotely observe and guide complex surgical procedures using augmented reality, artificial intelligence, and machine learning. This technology allows expert surgeons to connect with their peers globally, sharing knowledge and skills in real-time, regardless of their physical location. The platform is adaptable, compatible with various devices and software used in operating rooms, and can function effectively even in low bandwidth environments. Proximie aims to enhance surgical practices by democratizing access to expert guidance and fostering collaboration among medical professionals.

Zenflow

Series B in 2021
Zenflow, Inc. is a medical device company based in San Francisco, California, that specializes in providing innovative solutions for men suffering from benign prostatic hyperplasia (BPH) symptoms. Founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists, the company aims to address the significant unmet clinical need for effective urinary obstruction treatments. Zenflow's primary product is a spring-like device designed to gently prop open the urethra, restoring its normal function without damaging surrounding tissues. This approach prioritizes patient comfort and minimizes invasiveness, offering a less painful alternative to traditional treatments for urinary obstruction caused by an enlarged prostate.

1upHealth

Series B in 2021
1upHealth, Inc. operates a health data aggregation and centralization platform that facilitates secure data transmission between health systems and consumer applications. Founded in 2017 and based in Boston, Massachusetts, the company's platform consolidates health data from various electronic medical record systems into a digital health record that users can control and share with their healthcare providers. It also enables providers to access and query up-to-date patient information from multiple connected health systems. Additionally, 1upHealth's platform allows software developers to obtain clinical data from various clinics and hospitals, enhancing the ability to monitor patient activity and automate secure data sharing. By connecting disparate data sources, 1upHealth aims to improve healthcare outcomes for patients while promoting interoperability within the healthcare ecosystem.

Firefly Health

Series B in 2021
Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.

OZiva

Series B in 2021
OZiva is a plant-based clean nutrition brand that specializes in fitness, hair, skin, men's health, women's health, and general wellness products. The brand focuses on creating a nutrition and fitness ecosystem that integrates ancient Ayurvedic principles with modern micronutrient science. By providing organic nutritional products, OZiva aims to assist individuals in making healthier lifestyle choices through effective dietary planning. Their offerings are designed to meet everyday nutritional needs, making it easier for customers to pursue healthy living. The company emphasizes convenience and accessibility, fostering a community that supports its users in their wellness journeys.

Innovusion

Series B in 2021
Innovusion, Inc. is a developer of advanced image grade LiDAR sensor systems tailored for level 4 and 5 autonomous vehicles and advanced driver-assistance systems (ADAS). Founded in 2016 and based in Sunnyvale, California, the company focuses on delivering high-performance perception solutions that combine range, resolution, and hardware-accelerated sensor fusion. Their compact sensor systems are designed for ease of integration and cost-effectiveness, making them suitable for demanding applications in the autonomous driving market. Innovusion's innovative technology positions it as a key player in the rapidly evolving landscape of autonomous transportation.

LakeShore Biopharma

Series B in 2021
LakeShore Biopharma is a global, fully integrated medical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection.

Cohort

Series B in 2021
Cohort’s solution enables Primary Care Providers (PCP) to significantly improve the scale, efficiency and outcomes of a new or existing Chronic Care Management (CCM) program while simultaneously providing them a powerful platform for clinical trial identification and enrollment.

Centivo

Series B in 2020
Centivo is a new type of health plan administrator that allows self-funded employers and clinicians to join forces and deliver high quality, affordable healthcare to their employees. An alternative to traditional insurance carriers or third-party administrators, Centivo offers the technology, network, claims processing, customer support, and population health management to fully administer health benefits for all or a portion of an employee population. The Centivo model emphasizes the partnership between individuals and their primary care team as the proper model to coordinate healthcare needs. Centivo’s clinical partners are dedicated to controlling costs and helping members navigate the healthcare system, aided by personalized patient/doctor matching tools. Members are rewarded for working with their primary care team and choosing high-value care and are supported through a user-friendly app and their concierge. Employers get an ally that diligently roots out waste and is accountable for performance. It was formed in 2017 and headquartered in New York, United States.

Odaseva

Series B in 2020
Odaseva is a company that specializes in data management solutions for large enterprises using Salesforce. Its platform provides comprehensive data governance that focuses on data protection, privacy, and operational efficiency. Key features include backup and recovery, archiving, monitoring of governor limits, and compliance with regulatory requirements such as GDPR. Odaseva's tools enable businesses to manage their Salesforce data effectively, ensuring its confidentiality, integrity, and availability. By offering a range of integrated security products and services, Odaseva empowers organizations to take full control of their data, mitigate risks, and accelerate their digital transformation initiatives.

Carrot Fertility

Series B in 2020
Carrot Fertility, Inc. specializes in providing comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey on a global scale. The company's offerings include services such as egg freezing, in vitro fertilization, adoption, donor and gestational carrier services, as well as a premium pharmacy experience for fertility medications through Carrot Rx. Additionally, Carrot Pregnancy provides virtual access to experts and on-demand doctor-approved content, while the Carrot Card allows employees to use a flexible debit card for their fertility-related expenses. By customizing these benefits, Carrot Fertility aims to deliver financial, medical, and emotional support for individuals pursuing parenthood. Founded in 2015 and headquartered in San Francisco, California, the company also maintains offices in Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Avalyn Pharma

Series B in 2020
Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Rallybio

Series B in 2020
Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.

SonderMind

Series B in 2020
SonderMind is a digital health and telehealth company based in Denver, Colorado, that aims to enhance access to behavioral health services. Founded in 2014, it operates an online directory connecting individuals with independent professionals offering mental health, massage, acupuncture, and nutrition services. The platform simplifies the process of finding well-matched therapists, allowing consumers to quickly access trusted care while enabling therapists to concentrate on patient treatment without the burden of administrative tasks. SonderMind combines various software tools and an integrated provider network to deliver high-quality behavioral healthcare, serving consumers, employers, and health systems effectively. The company's mission is to make behavioral health services more accessible and utilized.

Xilio Therapeutics

Series B in 2020
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

BenchSci

Series B in 2020
BenchSci is a developer of a research intelligence platform that leverages advanced artificial intelligence and machine learning to enhance biomedical discoveries. By translating both closed and open-access data into actionable recommendations, BenchSci enables researchers to optimize experiments, particularly in the area of antibody extraction. This innovative approach allows scientists to conduct more successful experiments efficiently, minimizing resource waste and accelerating drug discovery. The company's technology is utilized by pharmaceutical companies and over 4,300 research centers globally, underscoring its significant impact on the scientific community. BenchSci is backed by notable investors, including F-Prime, Gradient Ventures, and Inovia Capital.

Funnel

Series B in 2020
Funnel is a marketing analytics and reporting software that aims to streamline data collection for online advertisers and e-commerce companies. Founded in 2014 by Fredrik Skantze and Per Made, the company provides a platform that integrates with over 400 marketing and advertising sources. This allows businesses to automatically collect and structure advertising performance data, facilitating better decision-making regarding advertising spend and business growth. Funnel enables users to feed data into various tools, including Business Intelligence platforms, Data Warehouses, and visualization tools like Google Data Studio and Google Analytics. The company serves a diverse clientele, including e-commerce businesses, media agencies, brands, B2B enterprises, mobile applications, and gaming companies. Funnel operates from its headquarters in Stockholm, with an additional office in Boston.

Oviva

Series B in 2020
Oviva UK Limited is a healthcare company based in London that specializes in digitally-enabled behavior change programs focused on diet and lifestyle-related health conditions, particularly type 2 diabetes and obesity. Founded in 2015, Oviva has developed a unique platform that combines a smartphone app and learning portals to provide personalized coaching and nutritional advice. This approach allows patients to engage in behavior change without the need for in-person clinic visits, thereby improving health outcomes and reducing costs for healthcare systems by preventing complications associated with these conditions. By leveraging a network of qualified consultants, Oviva aims to support individuals in achieving better health through tailored interventions.

SnapDocs

Series B in 2019
Snapdocs, Inc. is a real estate technology firm based in San Francisco that specializes in creating a digital platform for mortgage closings. Founded in 2013, Snapdocs connects lenders, title companies, and notary signing agents to enhance the efficiency and accuracy of the closing process. The platform automates interactions and workflows, allowing for streamlined operations and improved customer experiences. It offers features that enable lenders to adopt digital closings, providing flexibility in closing types, while also allowing title and escrow clients to automate their workflows. Notary signing agents can showcase their qualifications, and home buyers gain early access to their closing packages, fostering a smoother transaction. By leveraging advanced automation and AI technology, Snapdocs aims to simplify the complexities of mortgage closings, ultimately saving time and reducing costs for all participants involved.

CareStack

Series B in 2019
CareStack is a single all-in-one platform on the cloud that combines dental practice management, patient engagement, practice marketing, and data analytics. CareStack is currently used by large and growing practices as an all-in-one solution to increase productivity, minimize costs, and improve patient dental care. CareStack's mission is to help dentists to have a better practice and a better life. Through their technology-led offerings, CareStack will elevate dental offices to a higher degree of financial success.

Insilico Medicine

Series B in 2019
Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Buoy Health

Series B in 2019
Buoy provides a personalized all-in-one platform to help guide consumers back to health. Whether it's chatting about symptoms with Buoy Assistant to get help in the moment of sickness or researching benefits through Buoy Dashboard, Buoy is available 24/7 to help make self-diagnosis and navigating the healthcare system simple and easy. For employers, Buoy can be custom configured to surface benefits information and wellness programs, guide employees to in-network providers, and fully integrate with other health portals. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Optimus Ride

Series B in 2019
Optimus Ride is a self-driving vehicle company located in Boston, Massachusetts, specializing in the development of technologies aimed at creating efficient, sustainable, and equitable mobility systems. As a spinoff from MIT, the company leverages over 30 years of interdisciplinary research in self-driving technologies, electric vehicles, and mobility-on-demand systems. Its team possesses extensive industrial and entrepreneurial expertise, encompassing areas such as manufacturing robots, urban design, and shared vehicle fleet management. Optimus Ride focuses on implementing self-driving technology in geofenced environments, utilizing advancements in sensor fusion, mapping, computer vision, and machine learning. This enables a wide range of transportation solutions, from commercial vessel operations to various transit options.

RiskLens

Series B in 2019
RiskLens, Inc. specializes in cyber risk management software that enables organizations to quantify and manage cyber risk from a business perspective. The company's offerings include Cyber Risk Maturity, which assesses an organization's risk management capabilities and compliance with established frameworks; Cyber Risk Triage, a tool for prioritizing risk scenarios; and Cyber Risk Third-Party, which evaluates the risk management practices of external partners. Additionally, RiskLens provides Cyber Risk Quantification, a solution that estimates financial exposure to cyber events, as well as a standard value at risk model for both cyber and operational risks. The platform is designed for chief information risk officers and chief information security officers, assisting them in making informed decisions about cybersecurity investments and insurance policies. RiskLens serves a diverse range of sectors, including financial services, government, healthcare, education, and technology. Founded in 2011 and headquartered in Spokane, Washington, the company was previously known as CXOWare, Inc.

ABK Biomedical

Series B in 2019
ABK Biomedical combines the clinical market with biomaterials. It specializes in improving treatment options for patients with hypervascular tumors. The company is dedicated to transforming an interventional radiology procedure called embolization.

Vestwell

Series B in 2019
Vestwell is a developer of a digital savings platform focused on creating retirement plans for employees. The platform provides automated retirement investing options tailored for registered investment advisers (RIAs), aligning with regulatory requirements and various defined contributions for companies and their employees. By facilitating compliance and automation, Vestwell enables advisers to better engage with their clients in managing retirement savings.

Whatfix

Series B in 2019
Whatfix is a developer of a digital adoption platform that enhances user experience through personalized, real-time application guidance and support. By offering simulated application environments for training and no-code application analytics, Whatfix disrupts traditional training methods by delivering contextual and interactive support directly within applications. This approach enables organizations to improve user productivity, ensure process compliance, and streamline workflows across web, desktop, and mobile platforms. Additionally, the platform leverages generative AI to provide insights that help clients make informed decisions, ultimately driving greater adoption and efficiency in business-critical operations.

Beam Therapeutics

Series B in 2019
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients with serious diseases. Its therapeutic portfolio includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, and glycogen storage disorder 1A, as well as therapies for ocular and central nervous system disorders. Beam's base editing technology allows for targeted modifications at a single base in the genome without creating double-stranded breaks in DNA, positioning it as a pioneer in the field of genetic medicine. The company's pipeline includes several programs, such as BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201, reflecting its commitment to advancing genetic therapies.

Singular Genomics

Venture Round in 2019
Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

Genomics

Series B in 2018
Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.

Avidity Biosciences

Series B in 2018
Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.

Blispay

Series B in 2018
Blispay provides a streamlined in-store financing experience in the market. The Blispay Visa Card is a mobile-centric credit card in the industry, allowing merchants of all sizes to provide financing without any technical integration or financial obligation while customers get to enjoy instant issuance, 6-month special financing & 2% Cash Back. The company's first product is an everyday credit and financing solution that customers deserve and merchants need. Its founding team consists of experienced industry veterans from companies including BIll Me Later, PayPal, Bank of America, MBNA, Microsoft & Zynga.

Axoni

Series B in 2018
Axoni is a technology company that specializes in real-time data replication and distributed ledger software for the financial services industry. Founded in 2017, it serves major financial institutions, including banks, asset managers, hedge funds, and market infrastructure firms globally, with offices in New York and London. Axoni's platform facilitates the seamless integration of traditional financial technologies with blockchain systems, offering market information and deep analysis of trends. Its solutions enable rapid deployment of critical financial networks and automate real-time data sharing among market participants, enhancing the management of legal records, lifecycle events, and cash flow calculations.

RiskRecon

Series B in 2018
RiskRecon Inc. is a software company that specializes in third-party risk management by offering vendor security assessments. Founded in 2011 and based in Salt Lake City, Utah, RiskRecon provides a cloud-based platform that delivers continuous monitoring and on-demand assessments of organizations' security practices. The platform analyzes third-party internet infrastructure and application presence, enabling users to objectively measure the quality of their security programs. By offering risk-prioritized action plans tailored to individual risk priorities, RiskRecon helps organizations effectively control third-party risks and improve accountability among stakeholders, ultimately leading to better risk management outcomes.

Simon Data

Series B in 2018
Simon Data, Inc. is a company that specializes in developing and distributing a performance marketing platform designed to enhance customer engagement. Founded in 2013 and based in Brooklyn, New York, Simon Data provides a customer data platform that enables marketers to create complex customer segments and deliver personalized experiences. Its solutions include data ingestion, a personalization engine, multichannel automation, advanced experimentation support, and cohort-based funnel analysis. The platform's innovative approach allows organizations to implement personalization capabilities without the necessity of extensive customized data infrastructure, making it easier for brands to provide exceptional customer experiences globally.

WelbeHealth

Series B in 2018
At WelbeHealth, we envision a world in which every human being is able to participate fully in life through their final days. We serve frail seniors through a model of comprehensive medical and social care called PACE (Program of All-Inclusive Care for the Elderly), helping our participants live better, longer, and more independently. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture capital firms, we're looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors in our communities. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.

Unison

Series B in 2018
There is a smarter, better way to own your home. We call it home co-investing. Unison offers a smart new financing alternative for accessing your equity without taking on debt. We reduce debt and deliver a less risky way for homeowners, investors, and society to think about their most important asset - the home. We were founded in 2004 and are headquartered in San Francisco, California.

Benchling

Series B in 2018
Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform includes a suite of integrated applications that allow scientists to design, share, and document experiments, as well as manage biological entities like plasmids and antibodies. Key features include Benchling Insights, which enables users to visualize and collaborate on structured data, and a biological registration system for inventory tracking. Benchling's solutions cater to a diverse range of applications such as gene therapy, vaccines, and industrial biotechnology, serving scientists in biotech, pharmaceutical, academic, and government sectors. Established in 2012 and based in San Francisco, the company aims to enhance the speed and collaboration of life science research by providing tools that streamline workflows and facilitate critical R&D decisions.

Tempest Therapeutics

Series B in 2018
Tempest Therapeutics is a biotechnology company based in South San Francisco, California, that specializes in developing small molecule therapeutics for cancer treatment. Founded in 2011, the company focuses on innovative therapies that enhance anti-tumor immunity and directly target tumor cells. Its pipeline includes several clinical-stage candidates, notably TPST-1120, which blocks the PPAR-alpha pathway to stimulate immune response, and TPST-8844, designed to inhibit an enzyme that allows tumor cells to evade immune detection. Additionally, Tempest Therapeutics is working on compounds that target prostaglandins to counteract immune suppression. By pursuing these mechanisms, the company aims to create effective treatments that harness the body's own immune system to combat cancer.

Protenus

Series B in 2018
Protenus, Inc. is a company based in Baltimore, Maryland, that specializes in developing a compliance analytics platform for healthcare organizations in the United States. Founded in 2014, Protenus utilizes artificial intelligence to audit access to patient records, helping to identify risks such as inappropriate access and the misuse of controlled substances by hospital staff. The platform enables healthcare providers to proactively detect policy violations and anomalous behaviors, ultimately supporting safer patient outcomes while safeguarding the integrity of health data. Through its innovative solutions, Protenus aims to reduce risk and protect the reputation of healthcare organizations, affirming its commitment to both patient safety and organizational accountability.

Orchard Therapeutics

Series B in 2017
Orchard Therapeutics is a biopharmaceutical company based in the United Kingdom that specializes in developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which modifies a patient's own hematopoietic stem cells to create a targeted treatment administered in a single dose. Orchard's portfolio includes Strimvelis, the first autologous gene therapy approved by the European Medicines Agency for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Additionally, it is advancing clinical programs for various conditions, including metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has an extensive preclinical pipeline targeting mucopolysaccharidosis types I, IIIA, and IIIB. Orchard Therapeutics collaborates with leading institutions in gene therapy research, enhancing its efforts to transform the lives of patients with rare diseases in the UK, European Union, and the United States. Founded in 2015 and headquartered in London, it aims to provide sustainable clinical benefits through its innovative therapies.

Orient Speech Therapy

Series B in 2017
Orient Speech Therapy Center is a professional organization focused on enhancing children's speech and mental development. It specializes in providing speech and language therapy services for children with speech disorders, including those with autism. The center offers early screening, clinical diagnosis, and therapeutic interventions to support improved communication skills. To facilitate this development, Orient Speech Therapy has designed comprehensive curriculums, including the Star Curriculum, which targets children's speech, social skills, phonics, and oral muscle exercises. Through these tailored programs, the center aims to help children overcome communication challenges and foster their overall growth.

Stride Health

Series B in 2017
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.

Artemis Health

Series B in 2017
Artemis Health Inc. is a health data analytics company that offers a platform designed to assist self-insured employers in optimizing their benefit programs. Founded in 2013 and headquartered in Salt Lake City, Utah, the company provides actionable insights into benefits, identifying opportunities and gaps that employers can address. The platform enables users to pinpoint issues within their benefit offerings, share findings with relevant stakeholders, and implement solutions to enhance their programs. Additionally, it tracks the effectiveness of these solutions, allowing employers to make informed, data-driven decisions aimed at minimizing healthcare expenditures while improving employee health and wellness coverage.

Amphora Medical

Series B in 2017
Amphora Medical, Inc. is a Minnesota-based company that develops medical devices aimed at treating female overactive bladder (OAB) syndrome. Founded in 2011 and headquartered in Maple Grove, Minnesota, the company is focused on creating a novel cystoscopic device designed to enhance bladder function and improve the quality of life for individuals suffering from this condition. Utilizing minimally invasive procedures, Amphora Medical's innovative technology has the potential to offer significant benefits to patients dealing with OAB.

Checkmate Pharmaceuticals

Series B in 2017
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Quovo

Series B in 2017
Quovo Inc. is a New York-based company that develops a data platform focused on providing financial analytics and data management solutions for small- and mid-sized investors. The platform connects to millions of consumer financial accounts across over 14,000 institutions, allowing businesses to retrieve, organize, and analyze essential financial data. Quovo's offerings include tools for portfolio data normalization and reconciliation, as well as features that streamline client onboarding and facilitate ACH payments. Its services cater to a diverse clientele, including endowments, family offices, financial advisors, and individuals, enhancing their ability to manage investments and personalize financial services. Founded in 2009, Quovo operates as a subsidiary of Plaid Inc.

Pulmocide

Series B in 2017
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

Cytek Biosciences

Series B in 2017
Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment, primarily serving cancer and cell biology research. The company offers a range of products including the Cytek Aurora and Cytek Northern Lights flow cytometers, the DxP Athena flow cytometry system that utilizes advanced technology to resolve dim populations in a multicolor format, and the QbSure quality control program for assessing cytometer performance. Additionally, Cytek provides proprietary cFluor reagents designed to optimize instrument performance in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company, formerly known as Cytoville, Inc., rebranded to Cytek Biosciences, Inc. in August 2015.

Core Diagnostics

Series B in 2016
Core Diagnostics is a Clinical laboratory focused on Next Generation Diagnostics for disease stratification and therapy selection. We are focused on bringing the most advanced testing techniques and expertise to India. We aim to become the destination for all your high-end diagnostic needs.

Turnstone Biologics

Series B in 2016
Turnstone Biologics Inc. is a biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, it is dedicated to developing innovative viral immunotherapies aimed at improving survival rates for cancer patients. The company's lead product, RIVAL-01, utilizes a vaccinia virus backbone to deliver three key immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to enhance immune activity and reprogram the tumor microenvironment for optimal tumor eradication. Additionally, Turnstone Biologics is advancing next-generation tumor-infiltrating lymphocyte (TIL) therapies, which involve selecting and expanding the most effective T cells from a patient’s tumor to enhance the body’s immune response against solid tumors. Through these approaches, Turnstone aims to deliver breakthrough immunotherapies for cancer treatment.

Denali Therapeutics

Series B in 2016
Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.

US HealthVest

Series B in 2016
US HealthVest is an innovative behavioral healthcare firm that has redefined the psychiatric hospital space. De novo strategies and acquisitions of operating facilities with unrealized potential are the core of the US HealthVest business model. Each facility is structured to offer multiple service lines in order to serve the needs of specific patient population groups. The senior management team of US HealthVest has successfully built psychiatric hospital businesses which were acquired by public companies. Ascend Health was founded by Richard Kresch, M.D. in 2005 and was one of the largest private psychiatric hospital providers with nine freestanding facilities and nearly 900 beds. Ascend Health was sold to Universal Health Services (NYSE: UHS) in 2012. The predecessor company, Heartland Health Developments, also focused on psychiatric care and was sold to Psychiatric Solutions in 2004.

Caribou Biosciences

Series B in 2016
Caribou Biosciences, Inc. is a biotechnology company focused on cellular engineering and genome editing using CRISPR technology. Established in 2011 and based in Berkeley, California, the company leverages its CRISPR-Cas gene editing platform to facilitate precise modifications in DNA across various applications. These include developing therapeutics for human and animal health, creating disease models, enhancing agricultural traits, and advancing industrial biotechnology. Caribou Biosciences is particularly dedicated to the development of genome-edited cell therapies, including allogeneic CAR-T and CAR-NK cell therapies, aimed at improving outcomes for patients with severe diseases. The company’s innovative approach combines CRISPR with guide RNA to enable targeted DNA alterations, thereby contributing to advancements in both therapeutic development and biological research.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.